Angiotensin II Stimulation of Cardiac Hypertrophy and Functional Decompensation in Osteoprotegerin-Deficient Mice

Toshihiro Tsuruda1, Yoko Sekita-Hatakeyama2, Yilin Hao2

  • 1From the Department of Internal Medicine, Circulatory and Body Fluid Regulation (T.T., Y.S.-H., Y.H., S.S., K.K.), Division of Orthopaedic Surgery, Department of Medicine of Sensory and Motor Organs (S.K., T.F., T.S., E.C.), Department of Pathology (Y.A.), Frontier Science Research Center (J.K.), Faculty of Medicine, University of Miyazaki, Miyazaki, Japan; Department of Biochemistry, Matsumoto Dental University, Nagano, Japan (M.N., N.U.); and Department of Diagnostic Pathology, Nara Medical University, Nara, Japan (K.H.). ttsuruda@med.miyazaki-u.ac.jp.

Insights

Osteoprotegerin protects against angiotensin II-induced heart failure by preserving myocardial structure and function. This effect is independent of receptor activator of nuclear factor-κb ligand activity, highlighting osteoprotegerin

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Renal Physiology

Background:

  • Receptor activator of nuclear factor-κb ligand (RANKL) and osteoprotegerin (OPG) are implicated in heart failure.
  • Their specific roles in left ventricular remodeling, particularly with the renin-angiotensin system, require elucidation.

Purpose of the Study:

  • To investigate the pathophysiological roles of OPG and RANKL in angiotensin II-induced left ventricular remodeling.
  • To determine if OPG or RANKL influence cardiac structure and function during hypertrophy.

Main Methods:

  • Utilized osteoprotegerin knockout mice and RANKL-transgenic mice.
  • Administered angiotensin II via subcutaneous infusion to induce cardiac remodeling.
  • Assessed left ventricular structure, systolic function, fibrosis, and apoptosis.
  • Investigated the effects of OPG administration and anti-RANKL antibody treatment.

Main Results:

  • Angiotensin II induced eccentric hypertrophy and systolic dysfunction in OPG-deficient mice, with reduced fibrosis and increased apoptosis.
  • RANKL-transgenic mice exhibited concentric hypertrophy with preserved systolic function.
  • Recombinant OPG treatment ameliorated heart failure progression in OPG-deficient mice without impacting blood pressure.

Conclusions:

  • Osteoprotegerin plays a protective role in mitigating angiotensin II-induced cardiac hypertrophy and dysfunction.
  • OPG's beneficial effects appear independent of RANKL activity.
  • OPG may exert cardioprotective mechanisms through anti-apoptotic and profibrotic actions.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.4K